SCHEDULE: Artisan Partners Discloses 9.4% Stake in Veracyte

Artisan Partners Asset Management Inc. and its affiliates have reported a 9.4% beneficial ownership stake in Veracyte, Inc. common stock.

Summary

• Artisan Partners Asset Management Inc., along with Artisan Partners Holdings LP, Artisan Investments GP LLC, and Artisan Partners Limited Partnership, collectively hold a significant stake in Veracyte, Inc.
• The aggregate amount beneficially owned by these reporting persons is 7,370,467 shares of Veracyte, Inc. common stock.
• This ownership represents 9.4% of Veracyte's class of securities, based on 78,671,588 shares outstanding as of August 1, 2025.
• The reporting persons have shared voting power over 6,199,293 shares and shared dispositive power over all 7,370,467 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Veracyte, Inc.

Sentiment

Score: 7

Explanation: The filing indicates a significant and non-activist institutional investment in Veracyte, Inc., which is generally viewed positively as a vote of confidence from a major asset manager.

Positives

• A significant institutional investor, Artisan Partners, holds a substantial 9.4% stake in Veracyte, Inc., indicating confidence in the company.
• The filing explicitly states that the securities were acquired and are held in the ordinary course of business, not for control-influencing purposes, suggesting a long-term investment perspective.

Negatives

• NA

Risks

• NA

Future Outlook

NA

Industry Context

This filing reflects a significant investment by a major asset manager in Veracyte, Inc., a company operating in the healthcare diagnostics and biotechnology sector. Such institutional investments can signal market confidence in the company's long-term prospects within its industry.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by Artisan Partners may positively influence investor sentiment and potentially stabilize the stock price due to increased institutional backing.
• Company Management: A large, non-activist institutional investor can provide a stable shareholder base, allowing management to focus on long-term strategic goals.

Key Dates

Recommendation

The filing indicates a significant institutional investment, which is generally a positive signal. However, a Schedule 13G primarily reports ownership and does not provide financial performance data or strategic updates from the company itself. Therefore, while the institutional backing is favorable, a 'hold' recommendation is appropriate without further fundamental analysis of Veracyte's financial health and operational performance.

Keywords

Veracyte, Artisan Partners, Institutional Ownership, Common Stock, Beneficial Ownership, SEC Filing, Investment Adviser, Biotechnology, Healthcare Diagnostics